AstraZeneca Subsidiary Accused of Soliris Drug Market Monopoly

A unit of AstraZeneca Plc is facing a new antitrust suit claiming the company monopolized the market for a blood disorder drug by blocking competitors that wanted to launch similar, less-expensive versions of the medication.

Alexion Pharmaceuticals Inc. forced buyers to pay higher prices for brand-name Soliris by delaying the entry of generics at far lower prices, health insurer EmblemHealth Inc. alleged in a proposed class action filed Wednesday in the US District Court for the District of Massachusetts.

“The effect of Alexion’s misconduct is to net Alexion billions of dollars in revenue at the expense of end payers, including ...